CYC140

DRUG2 trials

Sponsors

Cyclacel Pharmaceuticals, Inc.

Conditions

ALL, AdultAML, AdultCLL, RefractoryCML, RefractoryMyelodysplastic SyndromesSolid Tumor, Adult Lymphoma

Phase 1

A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS

TerminatedNCT03884829

Cyclacel Pharmaceuticals, Inc.ALL, Adult, AML, Adult, CLL, Refractory +2

Start: 2019-03-25End: 2023-10-19Updated: 2024-09-19

A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

RecruitingNCT05358379

Cyclacel Pharmaceuticals, Inc.Solid Tumor, Adult Lymphoma

Start: 2022-04-14End: 2025-11-30Target: 330Updated: 2024-02-07